Urinary tract infection

ADAMEVE.COM ASKS HOW OFTEN DO YOU CLEAN YOUR SEX TOYS?

Retrieved on: 
Giovedì, Maggio 9, 2024
Bacterial vaginosis, Multimedia, LMFT, Bacteria, Marketing, Urinary tract infection, Candidiasis, Doctor of Philosophy, Adam and Eve, Habit, CST, Toy

This month, the results of their annual poll reveal how often people clean their sex toys.

Key Points: 
  • This month, the results of their annual poll reveal how often people clean their sex toys.
  • While nearly 43% of those polled said they cleaned their sex toys after every use, 47% of the respondents said they never clean their sex toys.
  • "I can't stress how important it is to clean your sex toys after each use," says Dr. Jenni Skyler, PhD, LMFT, CST, and resident sexologist at Adam & Eve.
  • Neglecting to clean your sex toys can lead to urinary tract infections, yeast infections and bacterial vaginosis.

Studies Show Diabetes Medicine Can Cause Urologic Complications

Retrieved on: 
Domenica, Maggio 5, 2024
Urine, Risk, American Urological Association, Abstract (summary), Abstract, MD, Research, Attention, Patient, Kidney, Albany Medical Center, Cardiovascular disease, Glucose, Annual general meeting, Chronic kidney disease, Urinary tract infection, SAN, Heart failure, Pharmaceutical industry

Researchers will present their study findings covering important updates on diabetes medicine and urologic complications in San Antonio, Texas, from May 3 to 6.

Key Points: 
  • Researchers will present their study findings covering important updates on diabetes medicine and urologic complications in San Antonio, Texas, from May 3 to 6.
  • “These meds are increasingly popular due to their ability to lower cardiovascular events and the risk of end stage renal disease.
  • They are now first line therapies for diabetes management in patients with cardiovascular disease, chronic kidney disease and heart failure,” said Dr. Inouye.
  • All three of these talks discuss the urologic sequelae we see in our clinics.”
    The following abstracts are covered in the moderated panel:

LC-Plasma-based Vaccine Research Selected for SCARDA Project

Retrieved on: 
Mercoledì, Maggio 8, 2024
Health, Infectious Diseases, Other Health, Research, Science, Pharmaceutical, Biotechnology, Infection, Kirin Holdings, Christian democracy, Postbiotic, Holding company, SARS-CoV-2, Bacteria, Plasma, Vaccine, Urinary tract infection, Immunization, Research and development, Virus, Kirin, Medical research, Multimedia, AMED, BBRC

We now announce that a proposal for our collaborative research has currently been accepted as a project for research and development into new modalities contributing to vaccine development by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) in the Japan Agency for Medical Research and Development (AMED).

Key Points: 
  • We now announce that a proposal for our collaborative research has currently been accepted as a project for research and development into new modalities contributing to vaccine development by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) in the Japan Agency for Medical Research and Development (AMED).
  • View the full release here: https://www.businesswire.com/news/home/20240507111790/en/
    This research aims at developing an intranasal LC-Plasma vaccine to induce innate immunity for prevention of respiratory virus infection.
  • SCARDA was established at AMED in March, 2022, based on the national strategy, to strengthen strategic research funding and to promote the formation of world-class research and development centers ( https://www.amed.go.jp/en/program/list/21/index.html ).
  • This project is to explore the potential of intranasal LC-Plasma vaccination to prevent respiratory infection with viruses including SARS-CoV-2 and influenza viruses.

The Christopher & Dana Reeve Foundation and Kessler Foundation Announce Novel Pilot Study to Improve Bladder Health in Individuals with Spinal Cord Injury

Retrieved on: 
Lunedì, Maggio 6, 2024
SCI, Brain, Urinary tract infection, Hope, Risk, Rehabilitation, Communication, MD, Kessler Institute for Rehabilitation, Urology, Catheter, Kessler Foundation, Tetraplegia, Butterfly, Clinical trial, Quality of life, Medical imaging

SHORT HILLS, N.J., May 6, 2024 /PRNewswire/ -- The Christopher & Dana Reeve Foundation and Kessler Foundation announced today a pilot study to revolutionize bladder management for individuals with spinal cord injuries (SCI). The study introduces the Butterfly iQ™, a cutting-edge, portable ultrasound device that enables those living with SCI to monitor their bladder volume at home, potentially mitigating the risk of urinary tract infections (UTIs), which often result from improper bladder management.

Key Points: 
  • SHORT HILLS, N.J., May 6, 2024 /PRNewswire/ -- The Christopher & Dana Reeve Foundation and Kessler Foundation announced today a pilot study to revolutionize bladder management for individuals with spinal cord injuries (SCI).
  • "After a spinal cord injury, disrupted communication between the bladder muscles and the brain can lead to UTIs and long-term health complications," says Marco Baptista, Ph.D., Chief Scientific Officer, Christopher & Dana Reeve Foundation.
  • The study will recruit ten participants from the Kessler Institute for Rehabilitation's Urology and SCI Outpatient programs.
  • This exciting pilot study offers new hope for individuals facing neurogenic bladder after an SCI.

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on: 
Lunedì, Maggio 6, 2024
Climate change, Agriculture, Risk, Climate, Health, Infection, AMR, Partnership, Research, Vaccine, History, Disease, Attention, Science, Urinary tract infection, Poverty, Mental health, Bill, Melinda French Gates, Notifiable disease, Novo Nordisk Foundation, Immunity, Tuberculosis, Prevalence, Global health, Pharmaceutical industry

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points: 
  • The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
  • "By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
  • To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
  • By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on: 
Lunedì, Maggio 6, 2024
Climate change, Agriculture, Risk, Climate, Health, Infection, AMR, Partnership, Research, Vaccine, History, Disease, Attention, Science, Urinary tract infection, Poverty, Mental health, Bill, Melinda French Gates, Notifiable disease, Novo Nordisk Foundation, Immunity, Tuberculosis, Prevalence, Global health, Pharmaceutical industry

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points: 
  • The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
  • "By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
  • To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
  • By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."

Studies Show Continued Efficacy of New UTI Vaccine

Retrieved on: 
Sabato, Maggio 4, 2024
UTI, Vaccination, Interview, Woman, American Urological Association, Abstract (summary), Abstract, MD, Urology, Research, Urinary tract infection, Urogynecology, Communication, Infection, Annual general meeting, SAN, Female, Northwell Health

SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss a new urinary tract infection (UTI) treatment as well as the UTI implications of weight management drugs.

Key Points: 
  • SAN ANTONIO, May 04, 2024 (GLOBE NEWSWIRE) -- Abstracts being presented at the American Urological Association's Annual Meeting discuss a new urinary tract infection (UTI) treatment as well as the UTI implications of weight management drugs.
  • Researchers will present their study findings covering important updates on UTI in San Antonio, Texas, from May 3 to 6.
  • “Fifty percent of women develop a urinary tract infection in their lifetime and a quarter will experience recurrent infections.
  • Treating this can be challenging for the patient and for providers,” said Dr. Lee.

Future of PF-07923568 in the Fight Against Respiratory Syncytial Virus - Market Size, Forecast, and Emerging Insights to 2032 - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Maggio 2, 2024
Health, Pharmaceutical, SWOT, Respiratory syncytial virus, Urinary tract infection, Disease, Patient, European, RSV, Global health, Pharmaceutical industry

In a significant development for the pharmaceutical industry, a comprehensive new report provides in-depth analysis and projections for the market potential of PF-07923568, a cutting-edge treatment for Respiratory Syncytial Virus (RSV).

Key Points: 
  • In a significant development for the pharmaceutical industry, a comprehensive new report provides in-depth analysis and projections for the market potential of PF-07923568, a cutting-edge treatment for Respiratory Syncytial Virus (RSV).
  • Respiratory syncytial virus is a major cause of respiratory illness worldwide, and the development of PF-07923568 represents a significant milestone in the fight against this pervasive virus.
  • The healthcare and pharmaceutical industries are closely monitoring the evolution of the PF-07923568 market landscape, which promises to play a significant role in advancing the treatment of Respiratory Syncytial Virus globally.
  • As medical science continues to push boundaries, reports such as these provide critical insights that help shape the future of healthcare delivery and patient care.

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Retrieved on: 
Venerdì, Maggio 3, 2024
FDA, Congress, Cancer, Urinary tract infection, Urinary diversion, Safety, Carcinoma, Survival, Johnson & Johnson, Immunotherapy, CRS, Abstract, Cohort, BCG, Disease, Bladder cancer, Dysuria, Patient, Metastasis, Medicine, NMIBC, AUA, Biopsy, BTD, Urination, Interim, Food and Drug Administration, SAN, Pharmaceutical industry

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ, who are ineligible for, or decline, radical cystectomy. These data were featured today in a plenary session (Abstract #P2-01) at the 2024 American Urological Association Annual Meeting (AUA) taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • "These results address an area of high unmet need for bladder sparing therapies in this patient population."
  • Results included an evaluation of 85 patients (median age of 71 years old: range 40-88; 32.9% with concurrent papillary disease) who received TAR-200 monotherapy.
  • The centrally confirmed complete response (CR) rate was 82.8% by urine cytology and/or biopsy (95% confidence interval [CI], 70.6-91.4).
  • Seven patients (8.2%) had Grade 3 or higher TRAEs and four patients (4.7%) had one or more serious TRAEs.

A link between breast changes and … UTIs?

Retrieved on: 
Giovedì, Maggio 2, 2024
UTI, CSHL, Urinary tract infection, TIMP1, Mouse, Risk, Pregnancy, Woman, Health, Cold Spring Harbor Laboratory, Research, Human, Metastasis, Cold, Infection, Menopause, Breast cancer, SPRING, Medical imaging

COLD SPRING HARBOR, N.Y., May 2, 2024 /PRNewswire/ -- Women's health is often talked about in terms of major, life-altering events like pregnancy and menopause. A new study from Cold Spring Harbor Laboratory (CSHL) underscores the importance of considering everyday occurrences' impact on women's well-being.

Key Points: 
  • The scientists found that UTIs in mice can provoke a bodily response that results in structural changes in breast tissue.
  • Cyrill notes that the breast changes that the team observed in mice with UTIs "were not directly caused by the infection itself.
  • Hormonal changes during pregnancy and menopause are known factors that can influence breast cancer risk .
  • They're now looking at how other changes women go through in their lifetimes might unexpectedly influence breast tissue.